Ionis Pharmaceuticals Inc. (IONS) and Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB) Contrasting side by side

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 568.84M 14.03 65.45M 0.51 104.36
Hemispherx Biopharma Inc. N/A 66.77 10.20M -0.26 0.00

Demonstrates Ionis Pharmaceuticals Inc. and Hemispherx Biopharma Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 represents Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. -11.51% -8.8% -2.4%
Hemispherx Biopharma Inc. 0.00% -118.5% -66.5%

Volatility and Risk

Ionis Pharmaceuticals Inc.’s volatility measures that it’s 138.00% more volatile than Standard and Poor’s 500 due to its 2.38 beta. Hemispherx Biopharma Inc.’s -0.53 beta is the reason why it is 153.00% less volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Ionis Pharmaceuticals Inc. are 8 and 8. Competitively, Hemispherx Biopharma Inc. has 1 and 1 for Current and Quick Ratio. Ionis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Hemispherx Biopharma Inc.

Institutional and Insider Ownership

The shares of both Ionis Pharmaceuticals Inc. and Hemispherx Biopharma Inc. are owned by institutional investors at 89.5% and 5% respectively. 0.2% are Ionis Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 2.6% of Hemispherx Biopharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. -8.51% -1.82% 19.71% 16.26% 1.5% 6.02%
Hemispherx Biopharma Inc. 9.67% -10.27% -23.04% -37.92% -38.85% -42.95%

For the past year Ionis Pharmaceuticals Inc. had bullish trend while Hemispherx Biopharma Inc. had bearish trend.

Summary

Ionis Pharmaceuticals Inc. beats Hemispherx Biopharma Inc. on 7 of the 10 factors.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companyÂ’s approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.